跳转至内容
Merck
CN

616431

反苯环丙胺盐酸盐

≥97% (HPLC), monoamine oxidase and histone demethylase inhibitor, solid

别名:

反苯环丙胺,盐酸盐,1X500MG, 组蛋白赖氨酸脱甲基酶抑制剂I,LSD抑制剂V,单胺氧化酶抑制剂I,反苯环丙胺,2-PCPA,TCP,(1R)-2-苯基环丙烷-1-胺盐酸盐,反式-2-苯基环丙胺盐酸盐,BHC110抑制剂V,LSD2抑制剂I,MOA抑制剂I,

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C9H11N · xHCl
化学文摘社编号:
分子量:
133.19 (free base basis)
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

反苯环丙胺盐酸盐, A cell-permeable phenylcyclopropylamine that inhibits the monoamine oxidase and histone demethylase activities.

SMILES string

Cl.N[C@@H]1[C@H](C1)c2ccccc2

InChI

1S/C9H11N.ClH/c10-9-6-8(9)7-4-2-1-3-5-7;/h1-5,8-9H,6,10H2;1H/t8-,9+;/m1./s1

InChI key

ZPEFMSTTZXJOTM-RJUBDTSPSA-N

assay

≥97% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
desiccated (hygroscopic)
protect from light

color

white to yellow

solubility

DMSO: 50 mg/mL

shipped in

ambient

storage temp.

2-8°C

Quality Level

Disclaimer

毒性:标准处理(A)

General description

一种细胞可渗透性苯环丙胺,通过与酶结合FAD形成共价加合物,可分别抑制MAO A/B(Ki分别为101.9M和16.0M)和LSD1/2(Ki分别为242.7M和180.0 M)的单胺氧化酶和组蛋白去甲基化酶活性,MAO A/B和LSD1/2是黄素依赖性胺氧化酶家族的四个成员。除了防止LSD1-CoREST(RE1沉默转录因子的共抑制因子)复合物介导的H3K4去甲基化(IC50<2 M)外,TCP还抑制LSD1-HCF-1(宿主细胞因子-1)复合物介导的H3K9去甲基化酶活性,这被证明是α-疱疹病毒HSV和VZV复制和潜伏性感染的基本机制。据报告,2 M TCP和10 M CHIR99061的联合治疗,可使Oct4/Klf4-转导的原代HNEKs(人新生儿表皮角化细胞)重新编码到iPS细胞(诱导多功能干细胞)中,尽管在用4-TFs(Oct44、Klf4Sox2和c-Myc)转导的培养物中,效率较低100倍。

Other Notes

Liang, Y., et al. 2009.Nat. Med.15, 1312.
Li, W., et al. 2009.Stem Cells27, 2992.
Karytinos, A., et al. 2009.J. Biol. Chem.284, 17775.
Hruschka, S., et al. 2008.Bioorg.Med. Chem.16, 7148.
Schmidt, D.M., and McCafferty, D.G.2007.Biochemistry46, 4408.
Lee, M.G., et al. 2006.Chem. Biol.13, 563.
Yoshida, S., et al. 2004.Bioorg.Med. Chem.12, 2645.

Packaging

用惰性气体包装

Preparation Note

复溶后,等分并冷冻(-20°C)。贮备溶液在-20°C下可稳定保存至多3个月。

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

相关内容

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持